Relation of interleukin-1β gene to treatment response in chronic patients infected with HCV genotype 4

Journal of Infection in Developing Countries

Volumn 7, Issue 11, 2013, Pages 851-858

  Omran, Moataza H ^a   Ibrahim, Noha E ^a   Youssef, Samar S ^a   Fatouh, Basma E ^a   Nabil, Wael ^a   El Shami, Magdy M ^b   El Awady, Mostafa K ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

HCV; Interferon therapy; Interlukin 1 ; Single nucleotide polymorphism; Sustained virological response

Indexed keywords

GENOMIC RNA; INTERLEUKIN 1BETA; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERLEUKIN 1BETA GENE; MAJOR CLINICAL STUDY; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887568949     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.3823     Document Type: Article

References (36)

1. Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis. C Annu Rev Immunol 25: 71-99.
2. Sharma SD (2010) Hepatitis C virus: Molecular biology & current therapeutic Options. Indian J Med Res 131: 17-34.
3. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL (2002) Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepato 37: 500-506.
4. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. Infect Dis 182: 28-35.
5. Shiratori Y, Omata M (2000) Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? J Gastroenterol Hepatol 15: 141-151.
6. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
7. Smith AJP, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine & Growth Factor Reviews 20: 43-59.
8. Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) Pathway. Sci Signal 3: 105.
9. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Laundy GJ (1998) Human cytokine gene nucleotide sequence alignments. Eur J Immunogenet 25: 83.
10. El-Awady MK, Youssef SS, Omran MH, Tabell AA, EL-Garf WT, Salem AM (2006) Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection. BMC Infectious Diseases 91: 1-7.
11. Ohno T, Mizokami M, Wu R, Saleh M, Ohba K, Orito E, Mukaide M, Williams R, Lau J (1997) New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a,1b,2a,2b,3a,3b,4,5a and 6a. J Clin Microbiol 35: 201-207.
12. Thakeb F, El-Serafy M, Zakaria S, Monir B, Lashin S, Marzaban R, El-Awady M (2005) Evaluation of liver tissue by polymerase chain reaction for hepatitis B virus in patients with negative viremia. World J Gastroenterol 43: 6853-6857.
13. rd Edition. Science.
14. nd Edition. Elsevier Academic press, USA.
15. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C (1995) Pretreatment serum hepatitis C virus genotype are the Main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22: 1050-1056.
16. Idrees M, Riazuddin S (2009) A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naïve chronic hepatitis C patients. BMC Gastroenterology 9: 5.
17. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (9):1259-1269.
18. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158: 177-181.
19. Fargion S, Fracanzani AL, Valenti L (2004) Treatment choices for people infected with HCV. Journal of Antimicrobial Chemotherapy 53: 708-712.
20. Lee JH, Kwon YD, Hong SH, Jeong HJ, Kim HM, Um JY (2008) Interleukin-1 beta gene polymorphism and traditional constitution in obese women. Int J Neurosci 118: 793-805.
21. Strandberg L, Mellström D, Ljunggren O, Grundberg E, Karlsson MK, Holmberg AH, Orwoll ES, Eriksson AL, Svedberg J, Bengtsson M, Ohlsson C, Jansson JO (2008) IL6 and IL 1B polymorphisms are associated with fat mass in older men: the MrOS Study Sweden. Obesity 16: 710-713.
22. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR (2002) Effect of weight reduction on liver histology and biochemistry inpatients with chronic hepatitis C. Gut 51 89-94.
23. Hadziyannis SJ, Sette JH, Morgan TR, Balan V, Diago M, Marcellin P (2004) Peginterferon- alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 5: 346-355.
24. Mizejewski GJ (2001) Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. ExpBiolMed 226: 377-408.
25. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol 43: 434-441.
26. Kishihara Y, Hayashi J, Yoshimura E, Yamaji K, Nakashima K, Kashiwagi S (1996) IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 41: 315-321.
27. Tian Z, Shen X, Feng H, Gao B (2000) IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. J Immunol 165: 3959-3965.
28. Ichikawa T, Nakao K, Nakata K, Yamashita M, Hamasaki K, Shigeno M, Abiru S, Ishikawa H, Ishii N, Eguchi K (2002) Involvement of IL-1 beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. Biochem Biophys Res Commun 29: 414-422.
29. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD (1999) Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi 62: 327-333.
30. Lapinski TW (2001) The levels of IL-1 beta,IL-4 and IL-6 in the serum and the liver tissue of chronic HCV- infected patients. Arch Immunol Ther Exp (Warsz) 49: 311-316.
31. Smith AJ, Keen LJ, Billingham MJ, Perry MJ, Elson CJ, Kirwan JR, Sims JE, Doherty M, Spector TD, Bidwell JL (2004) Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis. Genes Immun 5: 451-460.
32. Hellmig S, Titz A, Steinel S, Ott S, Folsch R, Hampe J, Schreiber JS (2005) Influence of IL-1 gene cluster polymorphisms on the development of H. pylori associated gastric ulcer. Immunol Lett 100: 107-112.
33. Ali L, Mansoor A, Ahmed N, Siddqi S, Mazhar K, Muazzam A, Qamar R, Khan K (2010) Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. Journal of General Virology 76: 4792-4797.
34. Mullar T, Mas-Marquas A, Sarrazian A, Wiese M, Halanqk J, Witt H, et al. (2004) Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 41: 652-658.
35. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ (2009) Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 461: 399-401.
36. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML (2009) IL 28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.